161 related articles for article (PubMed ID: 24858473)
21. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
22. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of CD44 and CD24 markers discriminates the epitheliod from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line: evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells.
Hsieh CH; Hsiung SC; Yeh CT; Yen CF; Chou YW; Lei WY; Pang ST; Chuang CK; Liao SK
Oncotarget; 2017 Feb; 8(9):15593-15609. PubMed ID: 28121626
[TBL] [Abstract][Full Text] [Related]
24. A critical role of CD29 and CD49f in mediating metastasis for cancer-initiating cells isolated from a Brca1-associated mouse model of breast cancer.
Vassilopoulos A; Chisholm C; Lahusen T; Zheng H; Deng CX
Oncogene; 2014 Nov; 33(47):5477-82. PubMed ID: 24317509
[TBL] [Abstract][Full Text] [Related]
25. MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
Su L; Luo Y; Yang Z; Yang J; Yao C; Cheng F; Shan J; Chen J; Li F; Liu L; Liu C; Xu Y; Jiang L; Guo D; Prieto J; Ávila MA; Shen J; Qian C
Cancer Res; 2016 Sep; 76(17):5054-67. PubMed ID: 27364559
[TBL] [Abstract][Full Text] [Related]
26. CD24⁺ ovary cancer cells exhibit an invasive mesenchymal phenotype.
Kang KS; Choi YP; Gao MQ; Kang S; Kim BG; Lee JH; Kwon MJ; Shin YK; Cho NH
Biochem Biophys Res Commun; 2013 Mar; 432(2):333-8. PubMed ID: 23396061
[TBL] [Abstract][Full Text] [Related]
27. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation.
Fu CH; Lin RJ; Yu J; Chang WW; Liao GS; Chang WY; Tseng LM; Tsai YF; Yu JC; Yu AL
Stem Cells; 2014 Aug; 32(8):2048-60. PubMed ID: 24802135
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic Plasticity Determines Cancer Stem Cell Therapeutic Resistance in Oral Squamous Cell Carcinoma.
Biddle A; Gammon L; Liang X; Costea DE; Mackenzie IC
EBioMedicine; 2016 Feb; 4():138-45. PubMed ID: 26981578
[TBL] [Abstract][Full Text] [Related]
29. Breast-cancer stem cells-beyond semantics.
Badve S; Nakshatri H
Lancet Oncol; 2012 Jan; 13(1):e43-8. PubMed ID: 22225725
[TBL] [Abstract][Full Text] [Related]
30. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon.
Kim HM; Haraguchi N; Ishii H; Ohkuma M; Okano M; Mimori K; Eguchi H; Yamamoto H; Nagano H; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S539-48. PubMed ID: 21879266
[TBL] [Abstract][Full Text] [Related]
31. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells.
Espinoza I; Miele L
Cancer Lett; 2013 Nov; 341(1):41-5. PubMed ID: 23973264
[TBL] [Abstract][Full Text] [Related]
32. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
33. CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment.
Wan X; Cheng C; Shao Q; Lin Z; Lu S; Chen Y
Tumour Biol; 2016 May; 37(5):6073-84. PubMed ID: 26608371
[TBL] [Abstract][Full Text] [Related]
34. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells.
Sarkar D; Shields B; Davies ML; Müller J; Wakeman JA
Int J Cancer; 2012 Jan; 130(2):328-37. PubMed ID: 21365650
[TBL] [Abstract][Full Text] [Related]
35. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative.
Biddle A; Liang X; Gammon L; Fazil B; Harper LJ; Emich H; Costea DE; Mackenzie IC
Cancer Res; 2011 Aug; 71(15):5317-26. PubMed ID: 21685475
[TBL] [Abstract][Full Text] [Related]
36. STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway.
Xu S; Yue Y; Zhang S; Zhou C; Cheng X; Xie X; Wang X; Lu W
J Exp Clin Cancer Res; 2018 Dec; 37(1):305. PubMed ID: 30518424
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.
Neelakantan D; Drasin DJ; Ford HL
Cell Adh Migr; 2015; 9(4):265-76. PubMed ID: 25482627
[TBL] [Abstract][Full Text] [Related]
38. Cancer stem cells from colorectal cancer-derived cell lines.
Yeung TM; Gandhi SC; Wilding JL; Muschel R; Bodmer WF
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3722-7. PubMed ID: 20133591
[TBL] [Abstract][Full Text] [Related]
39. Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24.
Liu AY; Cai Y; Mao Y; Lin Y; Zheng H; Wu T; Huang Y; Fang X; Lin S; Feng Q; Huang Z; Yang T; Luo Q; Ouyang G
Carcinogenesis; 2014 Mar; 35(3):537-45. PubMed ID: 24193512
[TBL] [Abstract][Full Text] [Related]
40. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.
Katsuno Y; Meyer DS; Zhang Z; Shokat KM; Akhurst RJ; Miyazono K; Derynck R
Sci Signal; 2019 Feb; 12(570):. PubMed ID: 30808819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
